Technical Analysis for FLXN - Flexion Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
FLXN closed up 0.09 percent on Friday, August 17, 2018, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|See historical FLXN trend table...|
|Date||Alert Name||Type||% Chg|
|Aug 17||NR7||Range Contraction||0.00%|
|Aug 17||Inside Day||Range Contraction||0.00%|
|Aug 16||Stochastic Reached Oversold||Weakness||0.09%|
|Aug 16||Oversold Stochastic||Weakness||0.09%|
|Aug 14||180 Bearish Setup||Bearish Swing Setup||-3.94%|
|Aug 14||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-3.94%|
|Aug 14||Outside Day||Range Expansion||-3.94%|
|Aug 13||Wide Bands||Range Expansion||-8.47%|
|Aug 13||Oversold Stochastic||Weakness||-8.47%|
|Aug 10||Inside Day||Range Contraction||-4.49%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Flexion Therapeutics, Inc. focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. Its lead product candidate includes FX006, an intra-articular, sustained-release triamcinolone acetonide, which has completed a Phase 2b dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor, which has completed a Phase 2a clinical trial to treat end-stage OA patients. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more FLXN news...
|52 Week High||32.25|
|52 Week Low||19.06|
|200-Day Moving Average||24.9835|
|50-Day Moving Average||25.438|
|20-Day Moving Average||23.5735|
|10-Day Moving Average||22.59|
|Average True Range||1.2217|
|Chandelier Exit (Long, 3 ATRs )||24.0649|
|Chandelier Exit (Short, 3 ATRs )||24.4851|
|Upper Bollinger Band||26.7183|
|Lower Bollinger Band||20.4287|
|Percent B (%b)||0.24|
|MACD Signal Line||-0.9507|
|Market Cap||699.68 Million|
|Num Shares||31.9 Million|
|Price-to-Earnings (P/E) Ratio||-7.05|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||23.24|
|Resistance 3 (R3)||23.15||22.64||23.02|
|Resistance 2 (R2)||22.64||22.30||22.68||22.94|
|Resistance 1 (R1)||22.28||22.10||22.46||22.37||22.87|
|Support 1 (S1)||21.41||21.43||21.59||21.50||20.99|
|Support 2 (S2)||20.90||21.23||20.94||20.92|
|Support 3 (S3)||20.54||20.90||20.84|
|Support 4 (S4)||20.63|